Netupitant - Palonosetron FDC - Global Market

Netupitant - Palonosetron FDC - Global Market Opportunity Assessment Study, 2012 - 2018

Netupitant – Palonosetron FDC – Global Market Overview

An oral therapy targeting two important pathways related to delayed and acute CINV by blocking P/NK1 receptors is known as netupitant palonosetron FDC. The palonosetron and netupitant combination is used for preventing vomiting and nausea that is caused by chemotherapy or cancer medicines. Both the netupitant and palonosetron blocks the signal to the brain thereby stopping the patient from nauseating and vomiting. The increasing rate of patient pool for chemotherapy stands a s a key factor augmenting the growth of the global netupitant palonosetron FDC market. The advent of novel conveyance techniques with work on patient consistence and the viability of blend treatment are acknowledged to work on by the patient pool.

The ascent in the patient opting for chemotherapy and the requirement for higher proficiency drugs for the treatment of cancer patients is supposed to drive the development of the market. In any case, the ongoing antiemetic adequacy is estimated to be around 70%-80% in patients treated with profoundly emetogenic cytotoxic drugs. An essential factor that makes sense of this poor reaction is inconstancy in genes encoding enzymes and proteins, playing an integral part in transport, metabolism, and receptors connected with antiemetic drugs.

Netupitant-Palonosetron is the main supported fixed-portion blend drug for the anticipation of chemotherapy-incited nausea and vomiting. The most well-known kind of cancer is the cellular breakdown in the lungs representing around 1.59 million deaths, worldwide. Only cancer is the main source of death around the world, representing almost 1.4 million new cases in 2012. Other forms of common cancer cases are breast cancer, liver cancer, stomach, and esophageal cancer. An estimated 8.2 million people worldwide died due to cancer. Cancer can be treated by a medical procedure, hormone therapy, chemotherapy, stem cell transplantation, precision medicine, radiation therapy, and designated therapy.

Hospital Pharmacy to Attract Higher Revenue Owing to Ease of Convenience and dependability

The global netupitant-palonosetron FDC market is categorized on the basis of distribution channel and regions. The sub-categories of the distribution channel segment include online pharmacy, retail pharmacy, drug stores, and hospital pharmacy. Among all these, the hospital segment is projected to witness notable growth in the coming years on account of the convenience of people and reliability. In terms of geography, the global netupitant palonosetron FDC market is widespread across five major regions namely North America, Asia Pacific, Europe, Latin America, and the Middle East and Africa. The FDC mix of netupitant and palonosetron has come to uncover proficient outcomes in Phase II clinical preliminaries. It is normal that the interest in this medication would witness high uptake as doctor and patient inclinations would move towards better treatment strategies for CINV. With the presence of better therapeutic facilities in some developing and developed nations, this market is likely to witness significant growth in the next couple of years.

The increasing prevalence of various cancer cases, coupled with the rising support from the government of various nations in the form of funding for research and development of better cancer therapeutics will aid in favor of the global netupitant palonosetron FDC market in the long run. Besides this, the advent of latest technology in detecting and fighting cancer will further help create new growth opportunities for the market in the long run.

Manufacturers of the global netupitant palonosetron FDC market are keen on the development of nobel drugs that will help promote the growth of this market in the coming years. Besides this, players are investing heavily on research and development of better therapeutics so as to generate significant revenues for the market on the one side and establish their brand name in the overall market competition.

Some of the key players of the global netupitant palonosetron FDC market include Tesaro, GlaxoSmith Kline plc., Helsinn Group, Eisai Pharmaceutical Pvt Ltd., Heron Therapeutics, and Acacia Pharma.

    Table of Content
    1. Preface
        1.1. Report Description
        1.2. Research Methodology
               1.1.1. Therapeutic Classes
               1.1.2. Order of Entry into the Market
               1.1.3. Indications
               1.1.4. Dosage & Formulation Type
               1.1.1. Company Overview
               1.1.2. Business Strategy
               1.1.3. Financial Overview
               1.1.4. Products and Services
               1.1.5. Recent Developments
    2. Executive Summary and Market Overview
    3. Market Analysis
        3.1. Introduction: Chemotherapy Induced Nausea and Vomiting (CINV)
               3.1.1. Description
               3.1.2. Aetiology/Causes for CINV 
               3.1.3. Current Drug Treatment Available 
        3.2. CINV Market Size & Opportunity Scenario (1/2)
               3.2.1. Global CINV Market (USD Million), 2009 - 2015 
               3.2.2. CINV Market (USD Million), by Geography, 2009 – 2015
               3.2.3. Global CINV Patient Pool (Million), 2009 – 2015
               3.2.4. CINV Target Patient Pool, by Geography, 2009 - 2015
        3.3. Description of Netupitant - Palonosetron FDC 
        3.4. Mechanism of Action of Netupitant - Palonosetron FDC 
        3.5. Clinical Trials Detail 
               3.5.1. Clinical Trial Detail – 1
               Trials Id - NCT01376297 
               3.5.2. Clinical Trial Detail – 2
                Trials Id - NCT01339260 
        3.6. Unmet Needs in CINV Market 
        3.7. Factors influential to the sales of Netupitant - Palonosetron FDC 
        3.8. Sales Projection: Netupitant - Palonosetron FDC 
               3.8.1. Global Target Patient Pool 
               3.8.2. Global Forecasted Sales in $ in 000\'s
        3.9. SWOT Analysis 
               3.9.1. Strength
               3.9.2. Weakness
               3.9.3. Opportunity
               3.9.4. Threat
       3.10. Overall License Agreement for Netupitant - Palonosetron FDC
               3.10.1. Global
               3.10.2. United States
               3.10.3. Europe
               3.10.4. Australia
               3.10.5. UK & Ireland
               3.10.6. South Korea
      3.11. Company Profile – Helsinn Group

Copyright © Transparency Market Research, Inc. All Rights reserved